NeoGenomics – Consensus Says Potential of -11.3% Down


NeoGenomics with ticker code (NEO) now have 10 analysts covering the stock. Analyst consensus indicates a rating of “Strong_Buy”. The target price is between 60 and 40.5 with an average TP of 47.95. Now, with the previous closing price of 54.05, that would indicate there is a drop of -11.3%. The 50-day MA is 46.66 while the 200-day moving average is 39.02. The company’s market capitalization is $ 6,270 million. Company website: http://www.neogenomics.com

NeoGenomics operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, clinical services and pharmaceutical services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical companies, academic centers and other clinical laboratories. It offers cytogenetic testing services to study normal and abnormal chromosomes and their relationship to disease; fluorescence in situ hybridization testing services focused on the detection and localization of the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure characteristics of cell populations; immunohistochemistry and digital imaging testing services to locate proteins in cells in a section of tissue, as well as to allow clients to see and use scanned slides and perform quantitative analysis for various spots ; and molecular testing services, which focus on DNA and RNA analysis, as well as the structure and function of genes at the molecular level. The company also offers morphological analysis which consists of analyzing cells under a microscope by a pathologist for diagnostic purposes; and testing services in support of its pharmaceutical clients’ oncology programs spanning discovery and commercialization, and acts as a reference laboratory providing testing services in anatomical pathology. NeoGenomics has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics was founded in 2001 and is headquartered in Fort Myers, Florida.

You can now share this on Stocktwits, just click on the logo below and add the ticker in the text to be seen.


About Hector Hedgepeth

Check Also

New study challenges widely held beliefs about Alzheimer’s disease

A new study challenges the dogma behind drug trials for Alzheimer’s disease. The study found …

Leave a Reply

Your email address will not be published.